Over 2 decades ago, the aldosterone antagonist eplerenone proved beneficial after MI complicated by left ventricular ...

CHICAGO -- Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the ...

Learn why the VictoryShares Dividend Accelerator ETF (VSDA) has underperformed its peers and why it may not be the best ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

2 Beaten-Down Dividend Stocks to Buy and Hold was originally published by The Motley Fool Despite soft inflation print, bond ...

Over 30 years, Cortes has led or co-authored hundreds of studies, including many trials of landmark drugs to treat chronic ...

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...